MinorDirect oral anticoagulants (factor Xa inhibitors)×Long-acting selective α1-adrenoceptor antagonist
Updated · Methodology
Mechanism
CYP3A4/5 is the main enzyme that metabolises apixaban in the liver. In laboratory studies, apixaban neither inhibited nor induced CYP enzymes, so it is not expected to change the elimination of drugs that these enzymes metabolise (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). According to laboratory data, CYP3A4 is also the main elimination pathway of doxazosin (doxazosin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Doxazosin is about 98% bound to plasma proteins, but in laboratory studies it did not change the protein binding of warfarin, digoxin, phenytoin or indomethacin (doxazosin SmPC, AEMPS). In clinical trials, people took doxazosin with anticoagulants without adverse interactions, although no formal interaction studies exist (doxazosin SmPC, AEMPS). The apixaban SmPC and label do not mention doxazosin or other alpha-blockers (apixaban SmPC, EMA, and label, US Food and Drug Administration, FDA).
Symptoms
In clinical trials, no adverse interactions occurred when people took doxazosin with anticoagulants (doxazosin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Doxazosin itself, especially at the start of treatment, can lower blood pressure on standing, with dizziness and weakness and, rarely, fainting (doxazosin SmPC, AEMPS). Apixaban raises the risk of bleeding. Common events are nosebleeds, haematomas, gum bleeding and blood in the urine (apixaban SmPC, European Medicines Agency, EMA). In apixaban studies in atrial fibrillation, low blood pressure was also a common adverse reaction, but the SmPC says nothing about combining apixaban with doxazosin (apixaban SmPC, EMA).
Management
According to the documents, no adjustment is needed. In clinical trials, people took doxazosin with anticoagulants without adverse interactions, and the apixaban SmPC and label do not mention doxazosin (doxazosin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and apixaban SmPC, European Medicines Agency, EMA). No formal interaction studies of doxazosin exist (doxazosin SmPC, AEMPS). At the start of doxazosin treatment, monitor blood pressure and warn the person to avoid situations where dizziness or weakness could lead to injury (doxazosin SmPC, AEMPS). In a person taking apixaban, watch closely for any sign of bleeding, and stop apixaban in case of severe bleeding (apixaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Doxazosina (nº registro 62655), sección 4.5 (2024)– AEMPS, CIMA, nº registro 62655 (Carduran Neo 4 mg comprimidos de liberación modificada, Viatris), ficha técnica 01/2024 (texto revisado 12/2018), secciones 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Doxazosina (nº registro 67973), sección 4.5 (2024)– AEMPS, CIMA, nº registro 67973 (Doxazosina Neo Stada 4 mg comprimidos de liberación prolongada EFG), ficha técnica 12/2024 (texto revisado 18/12/2019), secciones 4.4 y 4.5
- FDA: CARDURA (doxazosin) prescribing information (2022)– FDA, DailyMed setid eefc47bc-c10f-49bb-8ef7-5999f798ab39 (Roerig, Pfizer), versión 26 (SPL 20.01.2022, publicada 16.07.2026, texto revisado 12/2020), secciones 7 y 12.3